Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
REZILIENT3
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
- NCT05973773 ↗
- Active, not recruiting
- Taiho Oncology, Inc.
- Deep
We haven't built an HCP commentary report on REZILIENT3 (zipalertinib in untreated EGFR exon 20 insertion-mutated advanced nonsquamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REZILIENT3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 85 | |
| Podcasts | 14 | |
| YouTube | 12 | |
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- TAS6417
- Arms
- Part A (Safety Lead in) · Experimental
- Part B · Experimental
- Enrollment
- 285
- Primary outcomes
- Part A and B: The rate and severity of treatment emergent AEs
- Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)
- Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1
- Sponsor
- Taiho Oncology, Inc.
- Start
- Dec 18, 2023
- Primary completion
- May 27, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05973773 · updated Jul 30, 2026
Publications
linked from the registry- Heymach JV, Yu HA, Besse B, Cheng Y, Tan DS, Wei L, Wacheck V, Nishio M. REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. Future Oncol. 2025 Feb;21(5):549-556. doi: 10.1080/14796694.2025.2457294. Epub 2025 Feb 16. PubMed 39957151